South Korea's GC Biopharma Secures CMO Rights for Curevo's Shingles Vaccine
South Korean biopharmaceutical company GC Biopharma has signed a contract manufacturing agreement with Curevo Vaccine to produce amezosvatein (development name: CRV-101), a recombinant shingles vaccine currently under clinical development.
Curevo Vaccine | 13/10/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy